Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population
Valentina Cannone1, Alessia Buglioni2, S Jeson Sangaralingham2
1Cardiorenal Research Laboratory, Division of Circulatory Failure, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Division of Clinical Medicine, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Insights
Individuals with hypertension have higher aldosterone levels, which increase with more antihypertensive medications. This suggests a relative atrial natriuretic peptide deficiency, impacting hypertension treatment.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Hypertension Research
Background:
- Hypertension (HTN) is a widespread condition with complex pathophysiology.
- Aldosterone and atrial natriuretic peptide (ANP) play crucial roles in cardiovascular and renal homeostasis.
- Understanding the interplay between aldosterone, ANP, and antihypertensive (anti-HTN) medication use is vital for effective HTN management.
Purpose of the Study:
- To investigate the relationships among aldosterone levels, anti-HTN medication use, clinical profiles, and ANP levels in individuals with HTN.
- To determine if aldosterone levels differ between hypertensive and normotensive individuals.
- To examine how the number of anti-HTN medications correlates with aldosterone and ANP levels.
Main Methods:
- Analysis of a community-based cohort including individuals with and without HTN.
- Measurement of plasma aldosterone and ANP levels.
- Stratification of hypertensive participants based on the number of anti-HTN medications used.
- Evaluation of clinical characteristics, including metabolic and cardiovascular disease prevalence.
Main Results:
- Hypertensive individuals exhibited significantly higher serum aldosterone levels compared to normotensive participants.
- Aldosterone levels progressively increased with the number of anti-HTN medications used (0, 1, 2, and ≥3).
- Higher aldosterone levels were associated with a worse metabolic profile and increased prevalence of cardiovascular, renal, and metabolic diseases. ANP levels were inversely related to aldosterone levels in hypertensive patients.
Conclusions:
- Aldosterone levels are elevated in individuals with HTN and rise with increased anti-HTN medication use.
- A relative ANP deficiency may be associated with increasing aldosterone levels and anti-HTN drug use.
- Targeting aldosterone presents potential pathophysiologic and therapeutic implications for clinical HTN treatment.
Objective:
To investigate the relationships among aldosterone level, use of antihypertensive (anti-HTN) medications, clinical profile, and atrial natriuretic peptide (ANP) level in individuals with HTN.
Participants And Methods:
In a community-based cohort, we analyzed aldosterone plasma levels based on the presence (n=477) or absence (n=1073) of HTN. In individuals with HTN, we evaluated circulating aldosterone levels according to the number of anti-HTN drugs used, analyzed the associated clinical characteristics, and determined the relationship to the counterregulatory cardiac hormone ANP. Data were collected from August 25, 1997, through September 5, 2000.
Results:
Participants with HTN had higher serum aldosterone levels than those without HTN (6.4 vs 4.1 ng/dL [to convert to pmol/L, multiply by 27.74]; P<.001). When individuals with HTN were stratified according to the number of anti-HTN medications used, the increase in number of medications (0, 1, 2, and ≥3) was associated with higher aldosterone levels (4.8, 6.4, 7.10, and 7.9 ng/dL, respectively; P=.002), worse metabolic profile, and higher prevalence of cardiovascular, renal, and metabolic disease. In participants with HTN, ANP plasma levels were inversely related to aldosterone levels when the latter was divided into tertiles.
Conclusion:
In this randomly selected general population cohort, aldosterone levels were higher in individuals with HTN compared with normotensive participants. Aldosterone levels increased with anti-HTN medication use. These findings also suggest a relative ANP deficiency with increasing aldosterone levels and anti-HTN drug use. These studies have pathophysiologic and therapeutic implications for targeting aldosterone in the clinical treatment of HTN.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Conservation of Small Populations
What is Population Genetics?
Population Growth
Antihypertensive Drugs: Vasodilators

